Three genes not previously established as major genetic contributors to sarcoidosis — RFTN2, FAM117B, and RNF215 — may influence a person’s susceptibility to the inflammatory disease, according to a large genetic analysis. Using genetic information from more than 5,000 people living with sarcoidosis and nearly 500,000 without the disease,…
News
Sarcoidosis patients, caregivers, healthcare professionals, and researchers in the Mid-Atlantic will have the opportunity to come together to strengthen sarcoidosis care and build support networks at a free summit on Sept. 26 in Philadelphia. The Foundation for Sarcoidosis Research (FSR) is hosting the regional summit to allow patients…
Sarcoidosis appears to follow two main trajectories, and clinical and treatment features at diagnosis may help predict whether the disease will resolve within the first few years or persist, according to a large study in Sweden involving more than 9,000 adult patients. About seven in 10 patients had few…
The first participants have been enrolled in a global clinical trial that will test Priovant Therapeutics’ oral therapy candidate brepocitinib against a placebo in people with cutaneous sarcoidosis (CS) — a type of the autoimmune disease, with no approved treatments, in which clumps of immune cells form in…
Manual workers are overrepresented among people with sarcoidosis, a study in France showed. The trend is more pronounced when the disease involves the lungs (pulmonary sarcoidosis). This supports the hypothesis that occupational exposure to environmental toxins such as dust and chemicals increases the risk of sarcoidosis. It also…
Ear, nose, and throat (ENT) conditions may be underdiagnosed among adults with sarcoidosis, a large U.S. database study suggests. Research showed that sarcoidosis patients had more than 45% higher odds of having recorded diagnoses of sinus, swallowing, voice, and cranial nerve-related conditions than their matched peers without sarcoidosis. The…
The Foundation for Sarcoidosis Research (FSR) has selected more than a dozen clinical centers to serve as inaugural sites for its newly launched U.S.-based registry that aims to enroll at least 2,000 people with sarcoidosis. The FSR Clinical Data Registry will help support high-quality, standardized clinical data…
The Foundation for Sarcoidosis Research (FSR) is teaming up with the Patient Advocate Foundation to offer a new support program for people with sarcoidosis who need help navigating insurance, disability benefits, and other financial challenges. “For far too long, patients living with sarcoidosis have had to navigate…
People with pulmonary sarcoidosis who undergo a lung transplant face greater short-term risks after surgery but have better long-term survival compared with individuals undergoing the procedure due to other lung conditions. Those are the key findings of a large U.S. study that investigated outcomes among people for whom the…
Nearly 4 in 10 people with pulmonary sarcoidosis had a relapse after reducing or stopping treatment, according to a review of more than 50 published studies. Most studies with timing data reported relapses occurring within 1.5 years of reducing or discontinuing treatment. Black patients and those with more advanced…
Recent Posts
- Study identifies three genes that may influence sarcoidosis risk
- How music can help us process chronic pain, and even provide some relief
- Philadelphia summit to bring together sarcoidosis patients, experts
- Immune changes may help reveal disease activity in cardiac sarcoidosis
- In an inaccessible world, sometimes you can’t make lemonade
- Study finds sarcoidosis may follow 2 distinct paths after diagnosis
- Global trial now underway to test oral therapy for sarcoidosis in the skin
- As I decipher ongoing liver issues, at least my treasured coffee is good for me
- Study links manual work to higher risk of sarcoidosis
- Study points to overlooked ENT problems in adults with sarcoidosis